Turner Pope Investor Evening

RNS Number : 6749C

Avacta Group PLC

19 June 2019

 

19 June 2019

 Avacta Group plc

("Avacta", the "Company" or the "Group")

Turner Pope Investor Evening

Avacta Group plc (AIM: AVCT.L), the developer of Affimer^® biotherapeutics and reagents, is pleased to announce that the Group's Chief Executive, Alastair Smith, will be presenting at an investor evening hosted by Turner Pope Investments on Wednesday, 3 July 2019. The event will be held in London, EC2 and commence at 4pm.

To register your interest, please email [e-mail] or call on 0203 621 4124.

- Ends -

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
finnCap Ltd (Nominated Adviser and Joint Broker) Geoff Nash / Giles Rolls - Corporate Finance Tim Redfern - ECM WG Partners (Joint Broker) Nigel Birks / Nigel Barnes David Wilson / Claes Spang	Tel:  [phone] www.finncap.com Tel:  [phone] Tel:  [phone] www.wgpartners.co.uk
Turner Pope Investments James Pope / Ben Turner Yellow Jersey PR (Financial Media and IR) Sarah Hollins Harriet Jackson Zyme Communications (Trade and Regional Media) Katie Odgaard	Tel: [phone] www.turnerpope.com Tel: [phone] Tel: [phone] [e-mail] Tel: [phone] [e-mail]

About Avacta Group plc - https://www.avacta.com

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings.  Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes.  Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics. 

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

 

END

 

 

NRALLFFRRIITLIA